Despite encouraging clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from pharmacy benefit managers. The companies are https://fayllqc140180.blogripley.com/42839364/company-s-vyndamax-faces-is-meeting-pharmacy-benefit-manager-challenges-a-look-at-coverage-battles